文献速递系统性红斑狼疮其他结缔组织病

儿童自身免疫中的精准医学:leniolisib治疗由活化磷脂酰肌醇3-激酶δ综合征导致的儿童起病狼疮性肾炎

Precision Medicine in Pediatric Autoimmunity: Leniolisib Treatment of Childhood-Onset Lupus Nephritis Due to Activated Phosphoinositide 3-Kinase δ Syndrome.
PubMed 文献 · Arthritis Rheumatol · 2025-07-23

该研究对一名基因确诊APDS1(PIK3CD c.3061G>A,p.E1021K突变)的18岁女性难治性V型狼疮性肾炎患者进行机制探究,评估leniolisib(选择性PI3Kδ抑制剂)治疗反应,并用MIBI-TOF比较其肾组织免疫特征与12例儿童起病狼疮性肾炎及5例健康对照。leniolisib使PI3Kδ信号正常化并显著改善蛋白尿、补体水平及外周水肿;APDS1肾组织CD8+ T细胞比例显著高于典型狼疮性肾炎(21.6% vs 12.0%,P=0.0410),M1巨噬细胞比例42.0% vs 9.0%(P=0.1445)。

要点

  • APDS1相关狼疮性肾炎经传统免疫抑制治疗三年无效后,leniolisib使PI3Kδ信号正常化并改善蛋白尿、补体及水肿。
  • APDS1肾组织CD8+ T细胞比例为21.6%,显著高于典型狼疮性肾炎的12.0%(P=0.0410)。
  • APDS1肾组织M1巨噬细胞比例为42.0%,典型狼疮性肾炎为9.0%(P=0.1445),未达统计学显著。

核心结论

  • APDS1相关狼疮性肾炎具有特定的组织免疫特征,并对针对致病分子通路的靶向抑制产生应答。
  • 研究结果为自身免疫的遗传驱动因素提供机制见解,并支持对原发性免疫缺陷中难治性自身免疫表现采用通路特异性治疗方法。

研究设计与样本

  • 对一名基因确诊APDS1(PIK3CD c.3061G>A,p.E1021K突变)的18岁女性难治性V型狼疮性肾炎患者进行机制研究。
  • 通过临床参数和外周血淋巴细胞流式细胞术评估leniolisib(选择性PI3Kδ抑制剂)的治疗反应。
  • 采用MIBI-TOF表征肾组织免疫结构,将APDS1-LN组织特征与12例儿童起病狼疮性肾炎患者及5例健康对照进行比较。

主要发现

  • 经传统免疫抑制治疗三年未成功后,leniolisib治疗使过度活跃的PI3Kδ信号正常化,蛋白尿、补体水平及外周水肿显著改善。
  • MIBI-TOF显示APDS1-LN具有独特的组织特异性免疫病理,CD8+ T细胞比例显著增高(APDS1为21.6% vs 典型LN为12.0%;P=0.0410)。
  • M1巨噬细胞比例在APDS1为42.0%,典型LN为9.0%(P=0.1445),未达统计学显著;上述细胞聚集于伴免疫复合物沉积的肾小球周围。
  • 该免疫特征与组成性活跃的PI3Kδ通路对淋巴细胞耗竭及炎症表型的影响相一致。

临床怎么用

  • 作者认为,研究结果支持对原发性免疫缺陷中难治性自身免疫表现采用通路特异性治疗方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to investigate the mechanistic underpinnings and treatment response of lupus nephritis (LN) in activated phosphoinositide 3-kinase δ syndrome type 1 (APDS1) using pathway-specific therapy and advanced spatial proteomics. METHODS: We conducted mechanistic investigation of refractory class V LN in an 18-year-old female patient with genetically confirmed APDS1 (PIK3CD c.3061G>A, p.E1021K mutation). Response to leniolisib, a selective phosphoinositide 3-kinase δ (PI3Kδ) inhibitor, was evaluated through clinical parameters and flow cytometry of peripheral blood lymphocytes. Kidney tissue immune architecture was characterized using multiplexed ion beam imaging by time-of-flight (MIBI-TOF) spectrometry, comparing the APDS1-LN tissue signature with 12 patients with childhood-onset LN and 5 healthy controls. RESULTS: Following three years of unsuccessful treatment with conventional immunosuppressives, leniolisib treatment normalized hyperactive PI3Kδ signaling, resulting in significant improvements in proteinuria, complement levels, and peripheral edema. Multiplexed Ion Beam Imaging (MIBI)-Time-of-Flight (TOF) revealed a distinct tissue-specific immunopathology with significantly increased proportions of CD8+ T cells (21.6% in APDS1 vs 12.0% in typical LN; P = 0.0410) and M1 macrophages (42.0% in APDS1 vs 9.0% in typical LN; P = 0.1445) clustering around glomeruli with immune complex deposition. This immune signature aligns with the constitutively active PI3Kδ pathway's effect on lymphocyte exhaustion and inflammatory phenotype. CONCLUSION: This investigation advances rheumatology by demonstrating that APDS1-associated LN displays a specific tissue immune signature and responds to targeted inhibition of the causative molecular pathway. Our findings provide mechanistic insights into genetic drivers of autoimmunity and support pathway-specific therapeutic approaches for refractory autoimmune manifestations in primary immunodeficiencies.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Lim JP, Ahmadian M, Du H, et al. Precision Medicine in Pediatric Autoimmunity: Leniolisib Treatment of Childhood-Onset Lupus Nephritis Due to Activated Phosphoinositide 3-Kinase δ Syndrome. Arthritis Rheumatol. 2025. PMID: 40386960. doi:10.1002/art.43254

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。